Sygnature Discovery North America News and Activities

Sygnature Discovery North America is owned by Sygnature Discovery. Sygnature Discovery has a direct presence in 2 countries.

View the org chart displaying its 8 main executives

Most searched biographies at Sygnature Discovery North America

• Jade Dagher, General Manager
• Rene Coulombe, Senior Director, Structural Biology
• Harun Rashid, Director, In Vivo Pharmacology

Popular executive movements at Sygnature Discovery

• Stephen Young, Vice President, Business Development, has left the company  (posted on June 29 2026).
• Allan Jordan, who was Vice President of Oncology Drug Discovery, is promoted to Senior Vice President, Oncology Drug Discovery  (posted on June 29 2026).

Create your alert
to follow the executive moves at Sygnature Discovery North America.

Sygnature Discovery has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Sygnature Discovery North America

Social media about Sygnature Discovery North America

• Sygnature Discovery North America on Wikipedia, Google News & Yahoo Finance
• Sygnature Discovery North America on LinkedIn, X (Twitter) & YouTube